Stem Cells Targeting Inflammation as Potential Anti aging Strategies a pdf 6619 1
The review examines the concept of "inflammaging"—the chronic, low‑grade elevation of pro‑inflammatory mediators such as IL‑6, TNF‑α and C‑reactive protein that accompanies chronological aging and predicts a spectrum of age‑related diseases (cardiovascular disease, type‑2 diabetes, frailty, sarcopenia, cognitive decline, Alzheimer’s disease, and mortality). It argues that modulating this inflammatory milieu could preserve healthspan. Mesenchymal stem cells (MSCs), a subset of adult stem cells isolated from bone marrow, adipose tissue, umbilical cord, and other sources, possess unique immunomodulatory properties: they are non‑immunogenic, lack MHC‑II and costimulatory molecules, secrete anti‑inflammatory cytokines (IL‑10, TGF‑β, PGE2, HLA‑G) and suppress pro‑inflammatory cytokines (TNF‑α, IFN‑γ, IL‑1β). The paper details the International Society for Cellular Therapy criteria for MSC identification, their homing ability, and paracrine mechanisms. Pre‑clinical animal models (liver injury, lung fibrosis, traumatic brain injury, etc.) consistently show MSC infusion reduces pro‑inflammatory cytokines and increases anti‑inflammatory mediators. Clinical studies in rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Crohn’s disease, and graft‑versus‑host disease demonstrate MSC‑mediated shifts from pro‑ to anti‑inflammatory states, with reductions in IL‑6, TNF‑α, and CRP and improvements in disease activity. The authors propose that such MSC‑based immunomodulation could serve as an anti‑aging therapy by attenuating inflammaging, thereby mitigating frailty, sarcopenia, cognitive decline, and other age‑related pathologies. The review concludes with a call for further mechanistic studies, standardized MSC manufacturing, and clinical trials to validate MSCs as a viable anti‑aging intervention.
Topics
Inflammaging: Chronic Low‑Grade Inflammation as a Driver of Age‑Related Disease
Defines inflammaging, outlines how elevated IL‑6, TNF‑α, and CRP correlate with frailty, sarcopenia, cardiovascular disease, diabetes, cognitive decline, and mortality.